Parvovirus B19 infection in pregnancy-awareness and opportunities.

[1]  F. Bonvicini,et al.  Hydroxyurea inhibits parvovirus B19 replication in erythroid progenitor cells , 2017, Biochemical pharmacology.

[2]  M. Majigo,et al.  The magnitude and correlates of Parvovirus B19 infection among pregnant women attending antenatal clinics in Mwanza, Tanzania , 2017, BMC Pregnancy and Childbirth.

[3]  A. Ornoy,et al.  Parvovirus B19 infection during pregnancy and risks to the fetus , 2017, Birth defects research.

[4]  G. Gallinella.  Molecular Testing for Parvoviruses , 2017 .

[5]  F. Bonvicini,et al.  Enhanced inhibition of parvovirus B19 replication by cidofovir in extendedly exposed erythroid progenitor cells. , 2016, Virus research.

[6]  L. Tang,et al.  Original Research: Parvovirus B19 infection in children with sickle cell disease in the hydroxyurea era , 2016, Experimental biology and medicine.

[7]  F. Bonvicini,et al.  Parvovirus B19 Replication and Expression in Differentiating Erythroid Progenitor Cells , 2016, PloS one.

[8]  M. Söderlund-Venermo,et al.  A new quantitative PCR for human parvovirus B19 genotypes. , 2015, Journal of virological methods.

[9]  E. Kelly,et al.  Fetal thrombocytopenia in pregnancies with fetal human parvovirus-B19 infection. , 2015, American journal of obstetrics and gynecology.

[10]  G. Marano,et al.  Human Parvovirus B19 and blood product safety: a tale of twenty years of improvements. , 2015, Blood transfusion = Trasfusione del sangue.

[11]  J. Qiu,et al.  Human parvovirus B19: a mechanistic overview of infection and DNA replication. , 2015, Future virology.

[12]  F. Bonvicini,et al.  Antiviral effect of cidofovir on parvovirus B19 replication. , 2015, Antiviral research.

[13]  D. Oepkes,et al.  Intrauterine Blood Transfusion: Current Indications and Associated Risks , 2014, Fetal Diagnosis and Therapy.

[14]  A. MacGowan,et al.  Viral infections in pregnancy: advice for healthcare workers. , 2014, The Journal of hospital infection.

[15]  K. Vainio,et al.  Susceptibility to cytomegalovirus, parvovirus B19 and age‐dependent differences in levels of rubella antibodies among pregnant women , 2014, Journal of medical virology.

[16]  H. Nishiura,et al.  Estimating the Risk of Parvovirus B19 Infection in Blood Donors and Pregnant Women in Japan , 2014, PloS one.

[17]  A. Eis-Hübinger,et al.  The seroprevalence of parvovirus B19 infection in pregnant women in Sudan , 2014, Epidemiology and Infection.

[18]  J. Chiorini,et al.  The family Parvoviridae , 2013, Archives of Virology.

[19]  F. Bonvicini,et al.  Keeping Pace with Parvovirus B19 Genetic Variability: a Multiplex Genotype-Specific Quantitative PCR Assay , 2013, Journal of Clinical Microbiology.

[20]  E. Lopriore,et al.  Long‐term neurodevelopmental and cardiovascular outcome after intrauterine transfusions for fetal anaemia: a review , 2013, Prenatal diagnosis.

[21]  C. Mandl,et al.  Generation of a parvovirus B19 vaccine candidate. , 2013, Vaccine.

[22]  M. Melbye,et al.  Parvovirus B19 infection in pregnancy and subsequent morbidity and mortality in offspring. , 2013, International journal of epidemiology.

[23]  G. Gallinella.  Parvovirus B19 Achievements and Challenges , 2013 .

[24]  L. Mouthon,et al.  Intravenous immunoglobulin therapy for pure red cell aplasia related to human parvovirus b19 infection: a retrospective study of 10 patients and review of the literature. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[25]  P. Coyle,et al.  The lack of routine surveillance of Parvovirus B19 infection in pregnancy prevents an accurate understanding of this regular cause of fetal loss and the risks posed by occupational exposure. , 2013, Journal of medical microbiology.

[26]  F. Bonvicini,et al.  Parvovirus B19 in pregnancy: possible consequences of vertical transmission , 2012, Prenatal diagnosis.

[27]  A. Heath,et al.  Collaborative study to establish a World Health Organization International genotype panel for parvovirus B19 DNA nucleic acid amplification technology (NAT)‐based assays , 2012, Vox sanguinis.

[28]  K. Gloning,et al.  Serological and virological analysis of maternal and fetal blood samples in prenatal human parvovirus b19 infection. , 2012, The Journal of infectious diseases.

[29]  F. Walther,et al.  Intrauterine transfusion for parvovirus B19 infection: long-term neurodevelopmental outcome. , 2012, American journal of obstetrics and gynecology.

[30]  D. Bernstein,et al.  Safety and immunogenicity of a candidate parvovirus B19 vaccine. , 2011, Vaccine.

[31]  F. Bonvicini,et al.  Gestational and Fetal Outcomes in B19 Maternal Infection: a Problem of Diagnosis , 2011, Journal of Clinical Microbiology.

[32]  J. Möst,et al.  False-negative serology in patients with acute parvovirus B19 infection. , 2011, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[33]  F. Walther,et al.  Parvovirus B19 infection in pregnancy: new insights and management , 2011, Prenatal diagnosis.

[34]  K. Klingel,et al.  Risk of fetal hydrops and non-hydropic late intrauterine fetal death after gestational parvovirus B19 infection. , 2010, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[35]  G. Pasquinelli,et al.  Placental endothelial cells can be productively infected by Parvovirus B19. , 2009, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[36]  A. Andermann,et al.  Revisiting Wilson and Jungner in the genomic age: a review of screening criteria over the past 40 years. , 2008, Bulletin of the World Health Organization.

[37]  D. Oepkes,et al.  Thrombocytopenia in hydropic fetuses with parvovirus B19 infection: incidence, treatment and correlation with fetal B19 viral load , 2007, BJOG : an international journal of obstetrics and gynaecology.

[38]  M. Söderlund-Venermo,et al.  Improved diagnosis of gestational parvovirus B19 infection at the time of nonimmune fetal hydrops. , 2008, The Journal of infectious diseases.

[39]  N Hens,et al.  Parvovirus B19 infection in five European countries: seroepidemiology, force of infection and maternal risk of infection , 2007, Epidemiology and Infection.

[40]  David A. Anderson,et al.  Hepatitis B Virus Translocates across a Trophoblastic Barrier , 2007, Journal of Virology.

[41]  A. Ekman,et al.  Biological and Immunological Relations among Human Parvovirus B19 Genotypes 1 to 3 , 2007, Journal of Virology.

[42]  R. Chaoui,et al.  Fetal thrombocytopenia secondary to parvovirus infection. , 2007, American journal of obstetrics and gynecology.

[43]  H. Lankinen,et al.  Human parvovirus B19 infection during pregnancy--value of modern molecular and serological diagnostics. , 2006, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[44]  E. Maidji,et al.  Insights into viral transmission at the uterine-placental interface. , 2005, Trends in microbiology.

[45]  K. Furuya,et al.  Intrauterine therapy for parvovirus B19 infected symptomatic fetus using B19 IgG-rich high titer gammaglobulin , 2005, Journal of perinatal medicine.

[46]  G. Enders,et al.  Fetal morbidity and mortality after acute human parvovirus B19 infection in pregnancy: prospective evaluation of 1018 cases , 2004, Prenatal diagnosis.

[47]  J. Jordan,et al.  Human parvovirus B19 VP2 empty capsids bind to human villous trophoblast cells in vitro via the globoside receptor. , 2004, Infectious diseases in obstetrics and gynecology.

[48]  T. Hirbod,et al.  Revised clinical presentation of parvovirus B19-associated intrauterine fetal death. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[49]  N. Papadogiannakis,et al.  Frequency of human parvovirus B19 infection in intrauterine fetal death , 2001, The Lancet.

[50]  B. Jeune,et al.  An epidemic of parvovirus B19 in a population of 3596 pregnant women: a study of sociodemographic and medical risk factors , 2000, BJOG : an international journal of obstetrics and gynaecology.

[51]  J. Deloia,et al.  Globoside expression within the human placenta. , 1999, Placenta.

[52]  K. Sugamura,et al.  The incidence of, and factors leading to, parvovirus B19-related hydrops fetalis following maternal infection; report of 10 cases and meta-analysis. , 1998, The Journal of infection.

[53]  N. Young,et al.  Congenital anaemia after transplacental B19 parvovirus infection , 1994, The Lancet.

[54]  M. Anderson,et al.  An outbreak of erythema infectiosum associated with human parvovirus infection , 1984, Journal of Hygiene.

[55]  S. Jones,et al.  OUTBREAK OF APLASTIC CRISES IN SICKLE CELL ANAEMIA ASSOCIATED WITH PARVOVIRUS-LIKE AGENT , 1981, The Lancet.

[56]  B. Cant,et al.  PARVOVIRUS-LIKE PARTICLES IN HUMAN SERA , 1975, The Lancet.

[57]  Bender Ae.  Letter: Protein requirement. , 1974 .